Swedish Orphan Biovitrum (Sobi) has agreed a $8bn (SEK69.4bn) takeover offer from Advent International and Singapore’s wealth fund GIC. Sobi’s board of directors had unanimously recommended that shareholders
Moderna has initiated its submission process for the evaluation of a booster dose of its Covid-19 vaccine at the 50µg dose level, to the US Food and Drug
Merck and Ridgeback Biotherapeutics have initiated a Phase III clinical trial to evaluate investigational oral antiviral therapeutic molnupiravir to prevent Covid-19 infection. For the global MOVe-AHEAD study, individuals
Teva Pharmaceuticals and MedinCell’s new drug application (NDA) for their drug, TV-46000/mdc-IRM to treat schizophrenia has been accepted by the US Food and Drug Administration (FDA). Intended for
Claimed to have high clinical potential to treat Covid-19, Silmitasertib acts on the protein kinase CK2 pathway. As a CK2-inhibitor, it is believed to hinder the active viral
The US Food and Drug Administration (FDA) has approved an expanded indication for UCB’s Briviact (brivaracetam) CV as monotherapy or adjunctive therapy for the treatment of partial-onset seizures
Roche has decided to voluntarily withdraw the US accelerated approval for Tecentriq (atezolizumab) in combination with Abraxane (nab-paclitaxel) to treat patients with PD-L1-positive metastatic triple-negative breast cancer (mTNBC).
Inovio has secured approval from the Brazilian health regulatory agency, ANVISA, to start the international Phase III part of Phase II/III INNOVATE clinical trial assessing its Covid-19 deoxyribonucleic
Japan has approved AstraZeneca’s Forxiga (dapagliflozin) to treat chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). The Japanese Ministry of Health, Labour and Welfare
Eli Lilly and Company and Lycia Therapeutics have signed a multi-year collaboration and licensing agreement for the discovery and development of novel lysosomal targeting chimera (LYTAC) degraders. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.